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Background: Chlamydia is the most common sexually transmitted bacterial infection
in Scotland, and is associated with potentially serious reproductive outcomes,
including pelvic inflammatory disease (PID) and tubal factor infertility (TFI) in women.
Chlamydia testing in Scotland is currently targeted towards symptomatic individuals,
individuals at high risk of existing undetected infection, and young people. The
cost-effectiveness of testing and treatment to prevent PID and TFI in Scotland is
uncertain.
Methods: A compartmental deterministic dynamic model of chlamydia infection in
15–24 year olds in Scotland was developed. The model was used to estimate the
impact of a change in testing strategy from baseline (16.8% overall testing coverage;
0.4 partners notified and tested/treated per treated positive index) on PID and TFI
cases. Cost-effectiveness calculations informed by best-available estimates of the
quality-adjusted life years (QALYs) lost due to PID and TFI were also performed.
Results: Increasing overall testing coverage by 50% from baseline to 25.2% is
estimated to result in 21% fewer cases in young women each year (PID: 703 fewer;
TFI: 88 fewer). A 50% decrease to 8.4% would result in 20% more PID (669 additional)
and TFI (84 additional) cases occurring annually. The cost per QALY gained of
current testing activities compared to no testing is £40,034, which is above the
£20,000-£30,000 cost-effectiveness threshold. However, calculations are hampered
by lack of reliable data. Any increase in partner notification from baseline would be
cost-effective (incremental cost per QALY gained for a partner notification efficacy of
1 compared to baseline: £5,119), and would increase the cost-effectiveness of current
testing strategy compared to no testing, with threshold cost-effectiveness reached at
a partner notification efficacy of 1.5. However, there is uncertainty in the extent to
which partner notification is currently done, and hence the amount by which it
could potentially be increased.
Conclusions: Current chlamydia testing strategy in Scotland is not cost-effective
under the conservative model assumptions applied. However, with better data
enabling some of these assumptions to be relaxed, current coverage could be
cost-effective. Meanwhile, increasing partner notification efficacy on its own would
be a cost-effective way of preventing PID and TFI from current strategy.
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Chlamydia is the most common sexually transmitted bacterial infection in Scotland, as
in the rest of Europe [1,2]. In 2011 there were 18,961 diagnoses of genital chlamydia in-
fection in Scotland: 11,881 in women and 6,913 in men (and 167 of unknown gender)
[3]. Diagnoses are highest among young people [3]. In 2010, a quarter of young women
(25.6%) and 8.3% of young men aged 15–24 years were tested for chlamydia (16.8%
average coverage between women and men) [4,5]. Of these, 10.6% of females and 15.4%
of males were positive for chlamydia infection: an average positivity of 11.8% [3,4].
Chlamydia infection is often asymptomatic [6,7], so the number of diagnoses is an
underestimate of the total number infected. In the third National Survey of Sexual
Attitudes and Lifestyles (Natsal-3), 5.7% (95% C.I. 2.2, 14.2) of men and 3.1% (95% C.I.
1.1, 8.6) of women aged 16–24 in Scotland were infected with chlamydia: 4.4% preva-
lence when averaged between the sexes [8] (Scottish-specific prevalence data kindly
provided by Natsal-3 researchers). Infection is curable with antibiotics, and antibiotic
treatment is a standard part of the care of chlamydia-positive individuals. Untreated
infection spontaneously clears in the majority of individuals within some months
(1.13-1.63 years in women [9,10]), but infection can persist for years [11]. After clear-
ance (spontaneous or treatment-induced) individuals remain at risk of reinfection from
untreated infected partners or new (infected) partners, while “treated” individuals may
not clear their first infection due to treatment failure [12,13].
Chlamydia infection is associated with pelvic inflammatory disease (PID), tubal factor
infertility (TFI) and ectopic pregnancy (EP) [14]. PID is often assumed to be a necessary
intermediate stage between chlamydia infection and TFI or EP, though a proportion of
PID may be subclinical. Estimation of the risk of progression to secondary outcomes
through observational studies and randomised controlled trials is difficult for a number
of reasons, including: (1) the outcomes are rare; (2) the outcomes may occur many
years after chlamydia infection; (3) outcomes may not always be diagnosed; (4) treat-
ment may not prevent all outcomes; (5) outcomes have multiple causes besides chla-
mydia; and (6) the risk of complications may vary with duration or number of
infections [15,16]. Recently statistical modelling approaches have been applied to better
quantify the risks of long-term outcomes associated with chlamydia, based on observed
data, but with adjustment for inherent weaknesses of observational studies [17].
Most European guidelines for chlamydia management include treatment, partner no-
tification and health promotion, and in some instances, recommendation of retesting of
positives after three months [18-20]. National screening programmes exist in some
European countries (England: opportunistic screening programme; the Netherlands:
population register screening) while others have high levels of opportunistic testing in
the absence of an organised national programme (Denmark, Estonia, Iceland, Latvia,
Norway and Sweden). In Scotland, the 2009 Scottish Intercollegiate Guidelines Network
(SIGN) guidelines state that chlamydia testing should be focussed on symptomatic
patients and asymptomatic individuals at high risk of having an undiagnosed infection,
and targeted to young people [21]. There is no current recommendation for opportunistic
testing of all young people.
Robust estimates of the impact of testing programmes and their cost-effectiveness are
hampered by uncertainties in the risks of disease progression, quality-adjusted life years
(QALYs) applied to chlamydia and its sequelae [22], and the effectiveness of testing and
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level. Transmission dynamic mathematical models are an appropriate tool to investigate
the potential impact and cost-effectiveness of different testing strategies, and to explore
the effect of uncertainties in the underlying parameter assumptions. Here we apply the
latest estimates of progression, the effect of testing and treatment, and QALY loss
associated with progression, to a deterministic model to evaluate the impact and
cost-effectiveness of current and potential testing strategies to prevent PID and TFI in
Scotland.Methods
We developed a deterministic, compartmental dynamic model of chlamydia trans-
mission and outcomes in the Scottish population aged 15–24 years. We used this to
evaluate the impact and cost-effectiveness of current and potential testing strategies
(which correspondingly also include treatment) to prevent PID and TFI in Scotland.
We considered current chlamydia testing coverage and partner notification rates,
and potential alternative strategies. We estimated the total cost of chlamydia testing
(including cost of outcomes), the number of PID and TFI cases prevented, and the
cost per outcome prevented.Model structure
A compartmental deterministic model of the heterosexual transmission of chlamydia in
Scotland was developed and solved numerically (Runge–Kutta 4; dt = 0.01) in Berkeley
Madonna, illustrated in Figure 1. The model population was stratified by sexual activity
class i but not sex, with outputs then scaled to the numbers of females and males aged
15–24 years in Scotland, NTARGET_F and NTARGET_M. The reason for this approach is
that incorporation of sex would have necessitated complex model fitting to fit to the
unequal observed chlamydia prevalence, testing coverage and test positivity between
women and men. Most likely this would have necessitated making additional assump-
tions for the pattern of sexual mixing between different sexual activity classes by sex,
the way in which the numbers of partnerships between the sexes are balanced, treat-
ment seeking behaviour between the sexes, and the transmission probabilities for
women and men, and hence, introducing even greater uncertainty in the model. More-
over, the interpretation and resultant policy implications of a model fitted to unequal
testing coverage and unequal test positivity between the sexes, are unclear.
Individuals enter the model at age 15 susceptible to chlamydia infection, and leave at
age 25. Entry rate φ and ageing rate α were selected to maintain a constant population.
The proportion of the population in each sexual activity class, ri, and the partner
change rates per year for each class, ci, were based on the numbers of partners in the
past year reported in the second National Survey of Sexual Attitudes and Lifestyles
(Natsal-2) [23]. All modelled individuals (i.e., aged 15–24 years) can potentially form
partnerships with all other modelled individuals: there is no further stratification of the
model by age. We assumed slight assortative mixing, ε, between sexual activity classes.
This means that there is some tendency for individuals to form partnerships with other
individuals in the same sexual activity class as themselves, over and above the
Figure 1 Model structure. Individuals enter the model on their 15th birthday and exit on their 25th
birthday. All individuals entering the population are initially susceptible (S) to chlamydia infection, and enter
each sexual activity class i (defined by partner contact rate ci) in proportions corresponding to the fraction
of the population in each class (ri). The flows represent ageing into and out of the model (φ and α), and
chlamydia infection (into CT), recovery (into R) and reinfection (into CT’). Infection rates for each sexual
activity class are given by the force of infection, λi. In addition to natural recovery (δ), a proportion of
individuals recover by seeking treatment (SEEKTREATINF * DTREATED), while further fractions recover through
additional testing and treatment (COV * DTREATED), or by partner notification and treatment (PNe * POSPN)
applied to treated index cases. A proportion of females (half of the model population) with incident
infection develops PID, while a smaller proportion develops TFI. For a full explanation of the model
structure see Methods text.
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nership formation of each of the different sexual activity classes.
Individuals are infected with chlamydia according to the per-susceptible force of in-
fection λi. Recovered individuals remain equally susceptible to infection (Susceptible-
Infected-Susceptible (SIS) model). A proportion of females with incident chlamydia in-
fection progresses to PID at rate PID_risk, and a smaller proportion progresses to TFI
at rate TFI_risk. PID and TFI cases are counted for the age at incident chlamydia infec-
tion (15–24 years), although in reality there may be a substantial delay between infec-
tion and the outcome. Due to uncertainties in the natural history of chlamydia
outcomes and the effect of treatment, we conservatively assume that the outcome risks
are unaffected by treatment for chlamydia, and that the risks are the same whether the
incident infection is a first infection or a subsequent infection.
Once infected with chlamydia, individuals recover spontaneously from infection on
average after one year (rate δ). Otherwise, individuals may recover either: (1) by actively
seeking testing and treatment; (2) through additional testing and treatment; or (3) via
partner notification and treatment. Specifically, we apply a rate of active treatment
seeking (SEEKTREATINF) to those assumed to be at high risk of infection (e.g., symp-
tomatic individuals, or individuals engaging in high-risk behaviour). The positivity in
this group (POSSEEKTREAT) is higher than the population prevalence, but slightly lower
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We also apply a rate of additional testing to all individuals who would not otherwise
get tested (COV). Here we assume that the proportion infected is equal to the popula-
tion prevalence (PREV). Lastly, we apply a rate of partner notification (PNe) to treated
positive (index) cases identified through either additional testing or treatment seeking.
It is assumed that there is some loss-to-follow-up (1 - DTREATED) between testing and
treatment for positive cases identified by additional testing or through treatment
seeking, but not for partner notification (i.e., treatment is given at the same time as
partner testing). This assumption was informed by discussion with Scottish genitourinary
medicine clinicians.
Full model equations are given in the Additional file 1, along with the equations for
the model outputs (Additional file 1: Table S1). The model parameters are detailed in
Table 1. Of note, there is uncertainty in a number of the model parameters (Table 1).
As a consequence of this, and to enable ease of model fitting and subsequent interpret-
ation, we did not introduce further complexity in the model for which parameterisation
would be potentially even more problematic/uncertain: for example, symptomatic vs
asymptomatic chlamydia infection, chlamydia immunity or condom use, although for
condom use, the transmission probability will be an average across all partnerships and
will be the effective transmission probability, and thus will implicitly include average
condom use.Model fitting
The chlamydia transmission probability per partnership, β, and the additional testing
coverage at baseline, COV, were calibrated by fitting the model at equilibrium to 4.4%
average chlamydia prevalence between women and men (PREV) and to 16.8% average
overall testing coverage between women and men (i.e., all types of testing) (TEST),
using the curve fitting function in Berkeley Madonna. We assumed a baseline of 0.4
partners notified and tested/treated per treated positive index. This gave a transmission
probability of 0.346 per partnership, and 11.9% additional testing coverage.Analysis
We explored the impact of current and alternative strategies by varying both overall
testing coverage (TEST; recalibrating COV), and partner notification efficacy (PNe).
Stepwise values for the alternative overall testing coverage across a range we considered
plausible were obtained by multiplying the overall testing coverage at baseline (16.8%)
by 0.5, 1, 1.5, 2 and 2.5. The outcomes were the change in the number of PID and TFI
cases prevented per year from a baseline overall testing coverage of 16.8% and 0.4
partner notification efficacy, and the expenditure on testing and treatment per PID case
or TFI case prevented compared to no chlamydia testing (additional testing or treat-
ment seeking) or partner notification. The comparison for cost (and subsequent overall
cost-effectiveness calculations) was no testing in order to evaluate the total cost of
testing and treatment for all cases prevented, and not because no testing is a realistic
management strategy.
In our model, the full effect of changing coverage and/or partner notification activ-
ities is not realised until some time after the change is implemented. However, the time





Transmission probability per partnership β 0.346 per
partner
– Calibrated by model fitting Estimated by fitting model predictions to chlamydia
prevalence and overall testing coverage. Modelled by
fixing duration of infection and allowing transmission
probability to vary – method also used by Althaus
[24] and Clarke [25]
Rate of recovery from infection per year δ 1 per yr – [9,10] No estimates in men; likely shorter than in women.
Estimates in women from recent modelling studies:
14 months [9] and 16 months [10]. Assumed shorter
duration overall to include men. Model transmission
modified to fit to desired prevalence, and transmission
probability and duration correlated
Risk of PID in those with incident chlamydia PID_risk 0.16 0.06-0.25 [17] Range derived from literature estimates
Risk of TFI in those with incident chlamydia TFI_risk 0.02 0.01-0.04 [26] Range derived from literature estimates
Demography
Female population in Scotland aged 15–24 years NTARGET_F 335,518 – [5] Population estimate as at 30 June 2010
Male population in Scotland aged 15–24 years NTARGET_M 349,417 – [5] Population estimate as at 30 June 2010
Rate of entry into the model per year φ 1/10 per yr –
Rate of ageing from model per year α 1/10 per yr –
Sexual behaviour








Mixing between sexual activity classes ε 0.2 – [27] Based on previous estimates where 0 represents



















Table 1 Model parameters (Continued)
Testing and treatment
Baseline prevalence among females and males aged
15–24 years
PREV 4.4% – [8] Based on prevalence among 16–24 year olds in Scotland
(Scottish-specific prevalence data kindly provided by
Natsal-3 researchers)
Overall testing coverage TEST 16.8% 8.4%, 16.8%,
25.2%, 33.6%,
42.0
Stepwise values (0.5, 1, 1.5, 2, 2.5
increases relative to baseline)
across an assumed realistic range
Note: the overall testing coverage includes all types of test
(additional testing, treatment seeking and partner
notification) and is the coverage at baseline partner
notification efficacy (0.4). Changes in partner notification
result in small changes in overall coverage but which
are not shown on the figures for simplicity
Additional testing coverage COV 11.9% 2.3%, 11.9%,
21.5%, 31.0%,
40.5%
Calibrated by model fitting Estimated from fitting model predictions to chlamydia
prevalence and overall testing coverage
Percentage of additionally tested individuals, or
individuals seeking treatment (females or males)
identified as positive who are successfully treated
DTREATED 91% – NCSP 2011-2012 [28] NCSP target is 95%. It is assumed that treatment is only
given after a positive test result, and that there can
therefore be loss to follow-up between testing and
treatment. This does not include treatment failure,
which is not incorporated in the model
Treatment seeking behaviour
Proportion of all those infected who seek treatment SEEKTREATINF 0.2 – [24] Selected for convenience to differentiate treatment seeking
behaviour which is not dependent on policy i.e., based on
symptoms or contact with infected partner, and testing of
asymptomatic individuals that could be modified depending
on testing strategy adopted. Althaus et al. found that the
value of the proportion symptomatic and seeking treatment
a short time after infection did not have a substantial
effect on transmission dynamics
Proportion of all those seeking treatment who are
infected with chlamydia
POSSEEKTREAT 0.2 – Assumed realistic value Chosen to be slightly lower than assumed prevalence
among partners
Partner notification
Number of partners successfully notified and tested/treated
per treated index (from either additional testing or
treatment seeking testing) (=partner notification efficacy)
PNe 0.4 0.0-2.0 in
0.25
increments
[29] Range within the number of partners reported by index



















Table 1 Model parameters (Continued)
Percentage positive among partners tested POSPN 30% – [30]
Costs






[31] Does not vary with population prevalence. NAO says it
should be possible to do a test for £33 [32]
Cost of partner notification per partner, including testing





[31] Does not vary with population prevalence
Cost of treating PID CPID £163 – [33]
Cost of treating TFI CTFI £2,115 – [34] Cost of one round of IVF on the NHS (conservatively
costed in order to account for those infertile women
who do not undergo IVF)
Health state utility




[22] Applies for 3 months
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the change, but generally speaking most of the impact is realised within five years). In
practice, “real-world” factors such as speed of policy implementation, and other factors
such as age-dependent sexual mixing, will likely more strongly influence time taken to
reach full impact of changing testing strategy. For this reason, and to enable direct
comparison between strategies, it was decided to present all analyses of change in test-
ing strategy for the equilibrium state, i.e., time-independent.
Sensitivity analyses were performed for the change in the number of outcomes pre-
vented and the expenditure on testing and treatment per case averted, varying the as-
sumed PID and TFI risks. We selected a value for the overall testing coverage of 25.2%
(a 50% increase in overall coverage compared to baseline) for these analyses since this
was in the middle of the modelled range of overall coverages.
Cost-effectiveness calculation
We selected health state utility values of 0.9 for PID [35] (which applies for 3 months),
and 0.76 for TFI [35] (which applies for 1 year), from the values presented in Jackson
et al. [22]. The health state utility value for TFI may be lower than 0.76 for 1 year for
women who have not been able to get pregnant and/or who have endured several cy-
cles of IVF; however, this value needs to be an average across all women with TFI, some
of whom may never attempt to become pregnant and therefore remain unaware they
are infertile. We adjusted the value of 0.9 for 3 months for PID to apply for a year:
(0.25 * 0.90) + (0.75 * 1) = 0.975. The QALY estimate for each outcome is given by (1 -
heath state utility value). We calculated the cost of chlamydia testing per quality-
adjusted life year (QALY) gained:
Cost per QALY gained ¼ ½Annual cost of new scenario‐annual cost of baseline
scenario‐cost saving associated with treating PID
and TFI=½ Number of PID cases averted QALY for PIDð Þ
þ Number of TFI cases averted QALY for TFIð Þ
Sensitivity analyses were performed for the cost per QALY gained at 16.8% coverage
compared to no testing: (1) varying chlamydia testing costs; (2) varying the number of
QALYs gained by averting PID and TFI; and (3) varying the effectiveness of treating
chlamydia to prevent PID and TFI. An overall testing coverage of 16.8% (i.e., current
overall coverage) was selected since the cost-effectiveness of current testing strategy is
unknown and therefore it was considered that assessing the sensitivity of cost-
effectiveness calculations at this level would be of greatest interest.
Results
Impact of chlamydia testing
In Scotland the average chlamydia testing coverage among 15–24 year olds is 16.8%
and the average chlamydia prevalence is 4.4% in this age group. The number of part-
ners notified and tested/treated per treated index is assumed to be 0.4. These values
form the baseline strategy (current testing situation) for comparison with alternative
testing strategies.
The modelled test positivity at baseline testing strategy is 9.3%, which is similar to
the average observed positivity among females and males (11.8%). In Scotland, we
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rently occur annually which are attributable to a chlamydia infection aged 15–24 years
old. Under current testing strategy we estimate that a further 2,062 cases of PID and
258 cases of TFI are prevented from occurring every year. The total annual cost of test-
ing and treatment at this level is estimated from the model to be about £5.4 million.
In the model, increasing testing coverage by 50% from baseline to 25.2% results in
fewer outcomes per year (703 fewer PID, 88 fewer TFI: a 21% decrease in the number
of cases occurring, or 34% increase in the number of cases prevented, compared to
baseline) (Additional file 1: Figures S1a and S1b). If the overall testing coverage is
reduced by 50% from current levels to 8.4%, there will be an increase in outcomes (669
additional PID, 84 additional TFI: a 20% increase in the number of cases occurring, or
32% decrease in the number of cases prevented, compared to baseline) (Additional
file 1: Figures S1a and S1b). Increasing partner notification results in fewer cases of
PID and TFI. For example, an increase from 0.4 to 1 partners notified and tested/
treated per positive treated index (16.8% overall coverage) results in an additional
372 and 47 PID and TFI cases prevented each year, respectively (Additional file 1:
Figures S1a and S1b).
The model also shows that increasing partner notification always reduces the expend-
iture on testing and partner notification per case (PID or TFI) averted since partner
positivity is higher than the positivity in index tests (treatment seeking and additional
testing) (Additional file 1: Figures S2a and S2b). Increasing the overall testing coverage
generally leads to increased expenditure per case (PID or TFI) averted, due to
additional testing finding proportionately fewer infections than treatment seeking
behaviour (Additional file 1: Figures S2a and S2b). If partner notification is high, thenFigure 2 Cost per QALY gained for different levels of overall testing coverage compared to no
testing. Partner notification efficacy is 0.4. Note that there is no valid cost per QALY gained for no testing.
Calculations are for equilibrium state. For full table accompanying this Figure see Additional file 1: Table S2.
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prevented.
These results are sensitive to the assumed PID and TFI risks (Additional file 1:
Figures S3a and S3b). With higher PID and TFI risks, the number of cases pre-
vented rises and the expenditure per case averted decreases relative to the default
risks, and vice versa for lower risks. However, qualitative trends as a function of
changing testing strategy are unaffected.Cost-effectiveness of chlamydia testing and treatment to prevent PID and TFI
At current chlamydia testing levels of 16.8% overall testing coverage and 0.4 partners
notified and tested/treated per treated index, the cost per QALY gained for PID and
TFI compared to no testing is £40,034 (Figure 2 and Additional file 1: Table S2). This is
above the threshold cost-effectiveness of £20,000-£30,000 used by the National Institute
for Health and Care Excellence (NICE) [36]. The cost per QALY gained increases with
increased testing coverage, and decreases with decreased testing coverage. This is
because increasing testing coverage means increasing the number of additional tests
among young people generally: all those seeking treatment (who have higher test
positivity) are already being tested. At 8.4% overall testing coverage (50% of current
coverage), the majority of tests are done in individuals seeking treatment and their
partners, and the cost per QALY gained for PID and TFI compared to no testing is
£28,851, which is at threshold cost-effectiveness. However, it should be remembered
that more PID and TFI cases occur at lower testing coverage.
Increasing partner notification efficacy on its own under current overall testing cover-
age is a cost-effective way of preventing PID and TFI. For example, an increase from
0.4 to 1 results in an incremental cost per QALY gained of £5,119 compared to baseline
(16.8% overall testing coverage) (Figure 3 and Additional file 1: Table S3). Furthermore,
at overall testing coverage of 16.8% and a partner notification efficacy of 1, the overall
cost per QALY gained compared to no testing (i.e., taking all prevented cases into ac-
count) is £34,694, which is close to threshold cost-effectiveness (Additional file 1: Table S3).
Threshold cost-effectiveness for current testing coverage is reached at a partnerFigure 3 Incremental cost per QALY gained if partner notification efficacy is changed from baseline
(0.4). Overall testing coverage is 16.8%. Note that there is no valid cost per QALY gained for the
baseline strategy (0.4 partners notified and tested/treated per treated positive index; indicated by the
vertical line on the figure). Calculations are for equilibrium state. For table accompanying this Figure
see Additional file 1: Table S3.
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the cost-effectiveness of current overall testing coverage.
The cost per QALY gained is sensitive to the assumed testing cost (Figure 4) and
QALYs gained by testing (Figure 5). The current chlamydia testing strategy in
Scotland could be cost-effective if testing is cheaper (the exact cost of testing and
treatment in Scotland across all types of settings is unknown), or if morbidity due
to PID and TFI is greater, than we estimated. For example, the estimated cost per
QALY of 16.8% overall testing coverage compared to no testing would reach
threshold cost-effectiveness if testing costs were 20% cheaper (Figure 4), or if the
number of QALYs gained was around 30% higher than assumed (Figure 5). We
conservatively assumed that treatment does not reduce the risk of progression to
PID or TFI, but if treating chlamydia decreases the likelihood of subsequent
progression then the cost-effectiveness would also increase (Figure 6). Here,
threshold cost-effectiveness would be reached if treatment was 75% effective against
progression (i.e., if treatment of chlamydia positives reduced their risk of progres-
sion by 75%).Discussion
At current (16.8%) overall testing coverage and 0.4 partner notification efficacy, the
total annual cost of testing 15–24 year olds for chlamydia in Scotland is around £5.4
million. In the model, increasing testing coverage by 50% from baseline (16.8% overall
testing coverage and 0.4 partner notification efficacy) to 25.2% results in fewer
chlamydia-associated outcomes per year (703 fewer PID, 88 fewer TFI: a 21% decrease
in the number of cases occurring). If the overall testing coverage is reduced from
current levels by 50% to 8.4%, there will be an increase in outcomes (669 additional
PID, 84 additional TFI: a 20% increase). Increasing testing coverage generally leads to
an increase in the expenditure per case (PID or TFI) averted because proactive testing
finds proportionately fewer infections than testing those seeking treatment. However,
as partner notification is key to chlamydia control efforts given the high risk of
infection within partnerships, increasing partner notification reduces the expenditure
per case averted.Figure 4 Sensitivity analysis for the cost per QALY gained for baseline testing, varying the testing
costs. Baseline testing strategy is 16.8% overall testing coverage and 0.4 partner notification efficacy. The
cost per QALY gained is compared to no testing.
Figure 5 Sensitivity analysis for the cost per QALY gained for baseline testing, varying the QALY
gain. Baseline testing strategy is 16.8% overall testing coverage and 0.4 partner notification efficacy. The
cost per QALY gained is compared to no testing.
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under mid-range utility estimates for PID and TFI only, which is above the £20,000-
£30,000 threshold for cost-effectiveness used by NICE. The cost-effectiveness of
chlamydia testing could be underestimated if: (1) the health state utility value of either
PID or TFI applies for longer; (2) treatment costs for the outcomes are higher; (3)
ectopic pregnancy and male outcomes are included; and (4) testing coverage is higher
among women relative to men. Cost-effectiveness could be overestimated if chlamydia
causes fewer outcomes or if chlamydia prevalence is lower. We explored the sensitivity
of the cost per QALY gained for some of these in our model and found that cost-
effectiveness is highly sensitive to the assumptions made. In general we have made con-
servative assumptions that would tend to under-estimate cost-effectiveness, meaning
testing is likely to be more cost-effective than estimated here.
Our analysis shows that testing at 8.4% coverage is at threshold cost-effectiveness:
£28,851 per QALY gain for PID and TFI compared to no testing. However, at lower
levels of testing, more chlamydia-associated outcomes will occur and chlamydia preva-
lence could increase. In the model, treatment seeking individuals would still theoretic-
ally get tested if testing coverage was reduced. However, in practice, a reduced focus on
testing could reduce chlamydia awareness and therefore reduce the likelihood of
individuals seeking treatment, in addition to missing those asymptomatic individualsFigure 6 Sensitivity analysis for the cost per QALY gained for baseline testing, varying chlamydia
treatment effectiveness. Baseline testing strategy is 16.8% overall testing coverage and 0.4 partner
notification efficacy. The cost per QALY gained is compared to no testing.
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“treatment seeking” per se. Alternatively, increasing partner notification alone could
increase the cost-effectiveness of current chlamydia control (compared to no testing) to
NICE threshold levels.Limitations
We used a simple deterministic model for analytical tractability while capturing the
essential features of the dynamics of chlamydia infection and its complications.
Additional model complexity would have required further parameterisation and model
fitting which is currently not adequately supported by data and could potentially have
hampered model interpretation. However by definition this simple model does not
capture all possible factors which could influence the apparent cost-effectiveness of
chlamydia testing. We did not explicitly model partnerships, and recovered individuals
return to the susceptible pool and experience the same risk of infection as those never
infected. The rate of chlamydia reinfection in young women is high [37,38], which will
both reduce the impact of testing on prevalence, and increase the importance of part-
ner notification in controlling the continued spread of infection.
The risk of progression is applied uniformly to all cases of chlamydia at the point of
infection acquisition in the absence of reliable estimates of risk of progression to
outcomes with duration of infection. We showed in a sensitivity analysis that if we only
consider outcomes averted in people never infected, rather than additionally accounting
for outcomes averted due to earlier diagnosis and treatment, the effectiveness of testing
and treatment to prevent outcomes is underestimated. In addition, the description
of progression to PID or TFI from incident chlamydia is one of a number of possible
model structures and other structures may predict different effects of treatment
[39]. We attempted to overcome this through a sensitivity analysis of progression
probabilities.
If testing is done regularly and at high coverage, the mean duration of infection will
decrease but potentially reinfections will be more common. We did not incorporate
number of infections as a cofactor in progression risks. There is a potential for harm if
the risk of secondary outcomes increases with repeat infections [40]; however this has
not been observed in countries with high rates of chlamydia testing.
The model used is a deterministic compartmental model which responds very rapidly
to changes in the transmission dynamics as the whole population receives the interven-
tion equally and simultaneously. This may overestimate the effectiveness of testing,
since in practice the delays and variability inherent in implementing an intervention in
a heterogeneous population will slow and reduce its impact.
Lack of data hampers our ability to reliably estimate the level at which partner notifi-
cation is already done in Scotland, and hence the extent to which this can be increased.
Data from England suggest that partner notification efficacy is likely to vary substan-
tially between areas and healthcare settings (NCSP data [29]). Partner notification is a
good use of resources, both to treat partners who are highly likely to be infected, and
to prevent reinfection in the index case [31]. There is also uncertainty in estimates of
partner positivity rates. Theoretical studies have shown that positivity in partners is in-
sensitive to the population prevalence at around 33% [25]. The high positivity observed
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chlamydia which would fit with current testing strategy.
The costs of chlamydia testing and treatment need to be better defined for Scotland in
order to reliably inform cost-effectiveness calculations, which we showed are sensitive to
the assumed costs. For example, nurse-led testing is less expensive than clinician-led test-
ing. More generally, better understanding of the current organisation and provision of
chlamydia control activities in different settings in Scotland would help to define how test-
ing guidelines are currently implemented in practice, and thus, what changes could be
made to improve the management of chlamydia in the population.
Uncertainty in the amount of morbidity caused by PID and TFI and the associated
healthcare costs further reduces the reliability of cost-effectiveness calculations. We
used conservative values for the cost of managing a single episode of PID and one
round of IVF treatment for TFI. If these costs are higher, for example due to multiple
IVF rounds or PID episodes, then our analysis will underestimate the potential cost
savings from preventing PID and TFI. A recent systematic review [22] found that there
are significant problems in using current available values for health state utility (from
which QALYs are derived) for PID and TFI, and in fact in assigning values at all to TFI
in particular. Since cost-effectiveness is sensitive to, and indeed dependent on, the
assumed health state disutility associated with the outcomes, caution is advised in
interpreting the calculated values for the cost per QALY gained for current and alterna-
tive chlamydia testing strategies.Conclusions
Estimates of the impact and cost-effectiveness of chlamydia testing and treatment to
prevent PID and TFI in Scotland are important for guiding local decision-making on
the best use of available resources for chlamydia testing and treatment, in order to
effectively manage and prevent this common sexually transmitted infection and its
serious outcomes. Our findings are based on prevalence, coverage and costs specific to
Scotland, but have broader interest to other settings with similar chlamydia manage-
ment strategies or which are considering a change to their current testing policies. In
particular, our finding that partner notification is an efficient use of resources is likely
to hold true for other settings [31,41].
We found that, under current assumptions, current chlamydia testing strategy among
young people in Scotland is not cost-effective. However, there is significant potential
for current testing strategy to reach threshold cost-effectiveness, as lack of data to in-
form the calculations obligated the use of conservative assumptions. Significant data
gaps exist and the cost-effectiveness calculations should be updated when better
parameter estimates, particularly for the health state disutility associated with PID
and TFI, become available. Although lower testing coverage is at threshold cost-
effectiveness, we would expect to see more PID and TFI cases with less testing.
Scotland has high chlamydia test positivity even at 16.8% coverage, and decreasing test-
ing could lead to an increase in chlamydia prevalence, and uncertain future burden of
adverse reproductive morbidities.
Until cost-effectiveness calculations can be more reliably informed, particularly with
regard to the health state utilities, and on the basis of current model and parameter
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and treatment process would be advisable. One such way would be to increase the ex-
tent to which partner notification is done, which is cost-effective for any increase in
partner notification level compared to the current testing strategy.
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